(XOMA) XOMA - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 524m USD | Total Return: 65.9% in 12m
Avg Turnover: 5.94M
Qual. Beats: 0
Rev. Trend: 94.6%
Qual. Beats: 0
Warnings
Share dilution 18.2% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
XOMA Royalty Corporation (NASDAQ: XOMA) functions as a biotechnology royalty aggregator, specializing in the acquisition of economic rights to milestone and royalty payments from therapeutic candidates. The company focuses on a diversified portfolio ranging from early-stage Phase 1 and 2 clinical assets to late-stage and fully commercialized products licensed to third-party developers.
The royalty aggregator business model allows investors to gain exposure to drug development pipelines without the direct operational risks and high capital expenditures associated with internal R&D. By pivoting from a traditional biotech firm to a royalty-focused entity, XOMA generates revenue through the commercial success of its partners assets rather than proprietary manufacturing.
Investors may find additional insights on long-term valuation metrics by visiting ValueRay. In July 2024, the company officially rebranded from XOMA Corporation to XOMA Royalty Corporation to reflect its strategic emphasis on its evolving portfolio of global therapeutic rights.
- Portfolio expansion through acquisition of clinical-stage milestone and royalty rights
- FDA approval milestones and commercial launch timelines for licensed partner assets
- Recurring royalty revenue growth from established commercial-stage therapeutic products
- Interest rate fluctuations impacting the cost of capital for royalty acquisitions
- Concentration risk from dependence on partner clinical trial success and marketing efforts
| Net Income: 31.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 5.58 > 1.0 |
| NWC/Revenue: 236.5% < 20% (prev 247.6%; Δ -11.13% < -1%) |
| CFO/TA 0.02 > 3% & CFO 6.63m > Net Income 31.5m |
| Net Debt (52.4m) to EBITDA (41.9m): 1.25 < 3 |
| Current Ratio: 3.59 > 1.5 & < 3 |
| Outstanding Shares: last quarter (17.4m) vs 12m ago 18.23% < -2% |
| Gross Margin: 90.85% > 18% (prev 0.96%; Δ 8.99k% > 0.5%) |
| Asset Turnover: 14.95% > 50% (prev 17.62%; Δ -2.66% > 0%) |
| Interest Coverage Ratio: 2.90 > 6 (EBITDA TTM 41.9m / Interest Expense TTM 13.3m) |
| A: 0.32 (Total Current Assets 118.7m - Total Current Liabilities 33.1m) / Total Assets 271.9m |
| B: -4.48 (Retained Earnings -1.22b / Total Assets 271.9m) |
| C: 0.16 (EBIT TTM 38.5m / Avg Total Assets 242.3m) |
| D: -7.66 (Book Value of Equity -1.22b / Total Liabilities 159.0m) |
| Altman-Z'' = -19.50 = D |
| DSRI: 1.33 (Receivables 23.3m/18.2m, Revenue 36.2m/37.5m) |
| GMI: 1.06 (GM 90.85% / 96.23%) |
| AQI: 1.21 (AQ_t 0.56 / AQ_t-1 0.47) |
| SGI: 0.97 (Revenue 36.2m / 37.5m) |
| TATA: 0.09 (NI 31.5m - CFO 6.63m) / TA 271.9m) |
| Beneish M = -2.51 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 41.82 with a total of 51,700 shares traded.
Over the past week, the price has changed by -0.24%,
over one month by +5.79%,
over three months by +64.49% and
over the past year by +65.87%.
XOMA has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy XOMA.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44.5 | 6.4% |
P/E Forward = 20.3252
P/S = 10.7834
P/B = 6.0581
P/EG = -0.42
Revenue TTM = 36.2m USD
EBIT TTM = 38.5m USD
EBITDA TTM = 41.9m USD
Long Term Debt = 96.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 16.4m USD (from shortTermDebt, last quarter)
Debt = 147.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 22.6m
Net Debt = 52.4m USD (calculated: Debt 147.3m - CCE 95.0m)
Enterprise Value = 575.9m USD (523.6m + Debt 147.3m - CCE 95.0m)
Interest Coverage Ratio = 2.90 (Ebit TTM 38.5m / Interest Expense TTM 13.3m)
EV/FCF = 86.82x (Enterprise Value 575.9m / FCF TTM 6.63m)
FCF Yield = 1.15% (FCF TTM 6.63m / Enterprise Value 575.9m)
FCF Margin = 18.31% (FCF TTM 6.63m / Revenue TTM 36.2m)
Net Margin = 86.97% (Net Income TTM 31.5m / Revenue TTM 36.2m)
Gross Margin = 90.85% ((Revenue TTM 36.2m - Cost of Revenue TTM 3.31m) / Revenue TTM)
Gross Margin QoQ = 92.73% (prev 38.27%)
Tobins Q-Ratio = 2.12 (Enterprise Value 575.9m / Total Assets 271.9m)
Interest Expense / Debt = 9.02% (Interest Expense 13.3m / Debt 147.3m)
Taxrate = 0.02% (1.00k / 4.47m)
NOPAT = 38.5m (EBIT 38.5m * (1 - 0.02%))
Current Ratio = 3.59 (Total Current Assets 118.7m / Total Current Liabilities 33.1m)
Debt / Equity = 1.30 (Debt 147.3m / totalStockholderEquity, last quarter 112.9m)
Debt / EBITDA = 1.25 (Net Debt 52.4m / EBITDA 41.9m)
Debt / FCF = 7.89 (Net Debt 52.4m / FCF TTM 6.63m)
Total Stockholder Equity = 104.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.00% (Net Income 31.5m / Total Assets 271.9m)
RoE = 2.38% (Net Income TTM 31.5m / Total Stockholder Equity 1.32b)
RoCE = 2.72% (EBIT 38.5m / Capital Employed (Equity 1.32b + L.T.Debt 96.5m))
RoIC = 24.04% (NOPAT 38.5m / Invested Capital 160.2m)
WACC = 10.27% (E(523.6m)/V(670.9m) * Re(10.62%) + D(147.3m)/V(670.9m) * Rd(9.02%) * (1-Tc(0.00)))
Discount Rate = 10.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 20.37%
[DCF] Terminal Value 69.02% ; FCFF base≈6.63m ; Y1≈6.66m ; Y5≈7.06m
[DCF] Fair Price = 2.42 (EV 82.8m - Net Debt 52.4m = Equity 30.4m / Shares 12.5m; r=10.27% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.08 | # QB: 0
Revenue Correlation: 94.58 | Revenue CAGR: 183.9% | SUE: -0.11 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.17 | Chg30d=-23.08% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.26 | Chg30d=-32.03% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=0.79 | Chg30d=-28.61% | Revisions=+14% | GrowthEPS=-46.1% | GrowthRev=+16.5%
EPS next Year (2027-12-31): EPS=-0.05 | Chg30d=-107.30% | Revisions=+0% | GrowthEPS=-106.4% | GrowthRev=-13.6%
[Analyst] Revisions Ratio: -20%